Bristol Myers Squibb Company's total revenue fell 5% to $11.4bn in the fourth quarter and declined 0.5% to $46.2bn for 2022 in the first year of limited US generics launches for its multiple myeloma drug Revlimid (lenalidomide). But the big pharma focused on launching nine products during the past three years to replace that revenue, and in 2023 – the second year of limited generics – BMS expects those new drugs to not only fill the Revlimid gap but also play a role in 2% overall revenue growth.
Focus On Execution Pays Off, Sets BMS Up For Growth In 2023
Sales Of Nine New Drugs Set To Double From 2022 Total
Revenue declined in 2022 but the company expects it to increase 2% this year, offsetting an anticipated $3.5bn drop in Revlimid sales as new launches generate $4bn in 2023.
More from Business
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.